Pricing
Competitive Pricing at Every Volume
Avanta Pharma Group works through established 503A pharmacy partner relationships and combines purchasing volume across the clinics it supplies to negotiate rates that scale. Whether a practice orders a couple of dozen vials a month or several hundred, pricing is banded rather than gated behind a large minimum commitment, and the entry band is orderable at published list pricing without a call.
- Band 125-49 orders a month$80 per vial: list price, orderable with no call
- Band 250-99 orders a month$75 per vial
- Band 3100-199 orders a month$70 per vial
- Band 4200+ orders a month$65 per vial, the lowest published price
Published list pricing
- Semaglutide 1 mL (2.5 mg/mL)
- from $65per vial at 200+ a month
- Tirzepatide 1 mL (10 mg/mL)
- from $100per vial
- List pricing orderable with no call
- Volume pricing quoted on a call
- Shipping $25 standard, $45 overnight
- To the clinic or direct to the patient
Of the 19 suppliers Clinic Partner Guide tracks (12 sourcing platforms and 7 pharmacies), 2 publish per-vial rates a clinic can read before making contact, and Avanta Pharma Group is one of them. Most of this market quotes only after a call or a provider account, which is why the figures above are unusual rather than ordinary. They are Avanta Pharma Group’s own published list rates, read from its site on 2026-10-22, and you can check them there.
Rates shown are Avanta Pharma Group’s published list pricing and may change. Volume pricing is quoted per clinic, so the rate a practice pays depends on its own monthly volume, formulation and terms. Avanta Pharma Group is a pharmacy sourcing partner: compounding is performed by its 503A pharmacy partners rather than by Avanta Pharma Group itself.
503A vs 503B for a med spa or clinic: what to ask a supplier, and how to check the answer
As of 4 October 2026, 503A or 503B is a buying question: which facility fills your order? FDA describes 503A compounding as based on "valid patient-specific prescriptions", and says 503B outsourcing facilities may distribute on a provider's order "that is not for an identified individual patient". Ask your supplier which applies, then check FDA's list or the state board.
Which facility fills your order, and on what basis
As of 4 October 2026, 503A or 503B is a buying question: which facility fills your order? FDA describes 503A compounding as based on "valid patient-specific prescriptions", and says 503B outsourcing facilities may distribute on a provider's order "that is not for an identified individual patient".Source 1 Ask your supplier which applies, then check FDA's list or the state board.
Our guide 503A vs 503B: which compounding option your clinic needsSource 11 explains the two categories. This page starts where the definitions stop: what the distinction changes when a clinic chooses whom to order from, what to ask, and where to check the answer yourself.
Regulatory statements below are FDA's, quoted or attributed, and dated. Clinic Partner Guide compares suppliers and does not give legal advice.
What FDA says, side by side
Basis for an order. For a 503A pharmacy, FDA says "the drugs must be compounded based on the receipt of valid patient-specific prescriptions". A 503B outsourcing facility may distribute "either pursuant to a patient-specific prescription or in response to an order from a health care provider, such as a hospital, that is not for an identified individual patient (e.g., for office stock)".Source 1
Day-to-day oversight. FDA says "Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities."Source 2Of outsourcing facilities, FDA says they are "inspected by FDA according to a risk-based schedule".Source 1
Where a clinic can check it. For a 503A pharmacy, the license lookup of the state board that issued the license. For a 503B outsourcing facility, FDA's Registered Outsourcing Facilities table.Source 3
Source: FDA, read 4 October 2026.
One FDA line covers both: "Compounded drugs are not FDA-approved."Source 2A listing on FDA's table is a registration, not a product approval.
Regulatory context, for clinics whose orders include compounded GLP-1s: FDA's shortage listings for tirzepatide (December 2024) and semaglutide (February 2025) have ended, and FDA has since acted against marketing of compounded GLP-1s; what a 503A pharmacy may compound is patient-specific and varies by state. Source: fda.gov, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", read 2026-10-04.Source 4 FDA's 6 February 2026 announcement covers the marketing action.Source 5
What the distinction changes when you buy
- Order basis. FDA's description of section 503A ties compounding to "valid patient-specific prescriptions".Source 1 Ask a supplier working through a 503A pharmacy how prescriptions are handled with your orders. If it offers office-use orders, ask which facility fills them, under which registration.
- Verification route. A 503B outsourcing facility can be found on FDA's own table. A 503A pharmacy is licensed by a state, so the check runs through the board that issued the license. A supplier that will not name the facility leaves you with neither route.
- Consistency across orders. In a multi-pharmacy marketplace, in our methodology's words, "the filling pharmacy can vary by order".Source 6 Ask whether the facility, and its type, can change between orders or products, and how you are told.
- State rules. Whether your clinic may order or hold office stock from a given source depends on rules this page does not interpret. Ask your state board of pharmacy and your counsel, not a supplier's sales page.
Where to ask, by kind of supplier
Clinic Partner Guide's Compounded Sourcing Platform IndexSource 7 compares 12 sourcing platforms on 7 criteria read from their own public pages, scored 31 August 2026. Its category field shows who stands between your clinic and the facility, and so where the 503A or 503B question goes.Source 8
Direct Supply Partner (1 platform). Who fills the order: a pharmacy the supplier works with; the methodology defines the category as "A supplier a clinic contracts with directly". Put the question to the supplier, about that pharmacy by name.Source 6
Multi-Pharmacy Marketplace (5 platforms). Who fills the order: one of several pharmacies; "the filling pharmacy can vary by order". Put the question to the platform, for each order and each product.Source 6
GPO / Buying Network (1 platform). Who fills the order: a partner pharmacy. The record reads: "Order placement is still per partner pharmacy rather than one dedicated ordering portal." Put the question to the network, and to the partner pharmacy that fills each order.Source 8
Quote Engine (1 platform). Who fills the order: the pharmacy the clinic chooses. The record reads: "The service ends at introduction; the clinic then deals with the pharmacy directly." Put the question to the pharmacy you choose, directly.Source 8
Directory (4 labels). Who fills the order: the pharmacy the clinic contacts; each record states no ordering function. Put the question to the pharmacy you contact, directly.Source 8
The Banyan Network's record was verified 2 October 2026; the others were scored 31 August 2026. No criterion reason in the index names the facility that fills a given platform's orders, so the check below is the clinic's to run. What each publishes, not a verdict on service. For each kind of platform in more detail, seeSource 8 the four kinds of sourcing platform.
Disclosure: Clinic Partner Guide has a commercial affiliation with Avanta Pharma Group. Avanta is scored on the same criteria as every platform in the index, and no payment changes a score, a rank or an award. See our commercial disclosure: https://clinicpartnerguide.com/commercial-disclosure/Source 10
Five checks before the first order
Get the facility's name and type.
Ask: "Which facility fills our orders, and is it a 503A pharmacy or a 503B outsourcing facility?" Ask for the name and address as licensed or registered, not a brand name. From a marketplace or buying network, ask for every facility that may fill your orders.
Ask on what basis each order is filled.
A patient-specific prescription with each order, or a provider order not for an identified patient? Ask whether the answer is the same for every product you plan to order. If the supplier offers office-use supply, ask which facility fills it.
For a 503B outsourcing facility, find it on FDA's table.
Look for the facility by name in FDA's Registered Outsourcing Facilities table. Its fields include the most recent registration date, the last inspection date, whether a Form 483 was issued and the action based on the last inspection. The table lists facilities whose registration information was "determined to be complete by the data lock date for the latest weekly update of the table".Source 3 Record what you saw and the date, and ask the supplier about any entry you do not understand.
For a 503A pharmacy, check the license with the state board.
Use the license lookup of the board that issued it, not a screenshot from the supplier. NABP's Boards of PharmacySource 9 page links each state board's site. If the pharmacy ships into your state from elsewhere, check the license for every state you order into: our four-step license check sets out how.
Get it in writing, and ask how changes reach you.
Ask the supplier to confirm by email the facility, its type and the order basis, and how you will be told if any of them changes. Keep the email in your due-diligence file. FDA's table and a state license are true on the date you read them, so recheck before a large order.
What this page does not cover
This page covers which facility fills a clinic's order and how to check it. It does not say which kind of facility a clinic should use, what your state's rules on office stock are, or what any facility may compound. Those are questions for your state board of pharmacy, your counsel and the facility.
It does not cover clinical quality either, which our methodology does not assess.Source 6 Our index records what platforms published on the dates shown, and in our methodology's words, "A platform can change its pages the day after we read them."Source 6
Questions clinics ask
What does 503A vs 503B mean for who my clinic orders from?
It decides the order basis and how you verify the facility. FDA ties 503A compounding to "valid patient-specific prescriptions" and says 503B outsourcing facilities may also distribute on a provider's order "that is not for an identified individual patient".Source 1 Ask which facility fills your orders, by name, then check FDA's table or the state board.
How do I check whether a facility is a registered 503B outsourcing facility?
Look for the facility by name in FDA's Registered Outsourcing Facilities table. It shows registration dates, the last inspection date, whether a Form 483 was issued and the action based on the last inspection (read 4 October 2026).Source 3 If the facility is not there, ask the supplier why (FDA updates the table weekly); if it is a 503A pharmacy, check its license with the state board that issued it.Source 3
Does a 503A pharmacy fill office-stock orders?
Clinic Partner Guide does not answer that for any state. FDA's description of section 503A says "the drugs must be compounded based on the receipt of valid patient-specific prescriptions", and state rules differ.Source 1 Ask your state board of pharmacy and your counsel. Ask the supplier which facility would fill any office-use order, and under which registration.
Does registration with FDA mean a compounded product is FDA-approved?
No. FDA states: "Compounded drugs are not FDA-approved."Source 2A facility on FDA's Registered Outsourcing Facilities table is registered as an outsourcing facility. The listing is not an approval of any product it makes.
Does Clinic Partner Guide have a commercial relationship with any platform in this article?
Disclosure: Clinic Partner Guide has a commercial affiliation with Avanta Pharma Group. Avanta is scored on the same criteria as every platform in the index, and no payment changes a score, a rank or an award. See our commercial disclosure: https://clinicpartnerguide.com/commercial-disclosure/Source 10
Sources
- Regulatory / governmentU.S. Food and Drug AdministrationRetrieved
FDA wording on 503A and 503B order basis and inspection
- 2FDA, Compounding and the FDA: Questions and Answers (content current as of 16 September 2025)fda.govRegulatory / governmentU.S. Food and Drug AdministrationRetrieved
State board oversight sentence and the not-FDA-approved sentence
- Regulatory / governmentU.S. Food and Drug AdministrationRetrieved
Table fields and weekly update description
- Regulatory / governmentU.S. Food and Drug AdministrationRetrieved
Shortage-listing dates in the regulatory sentence
- Regulatory / governmentU.S. Food and Drug AdministrationRetrieved
FDA action on marketing of compounded GLP-1s
- Official primary sourceClinic Partner GuideRetrieved
- Official primary sourceClinic Partner GuideRetrieved
- Official primary sourceClinic Partner GuideRetrieved
- Professional bodyNational Association of Boards of PharmacyRetrieved
Links to each state board's site
- Official primary sourceClinic Partner GuideRetrieved
- Official primary sourceClinic Partner GuideRetrieved
What each 503A pharmacy partner publishes about pricing
There is no standard 503A compounding pharmacy price for clinics, and the reason is disclosure rather than variation alone: of the 12 sourcing platforms in this index, one publishes actual clinic rates. The rest either describe how pricing works without saying what it costs, or publish nothing about price and quote only after a call. Read as at 2026-08-31, except where a row gives a later date.
| Platform | Clinic pricing | What is published |
|---|---|---|
| Avanta Pharma Group | Rates published | Publishes a full per-vial retail schedule for compounded semaglutide and tirzepatide by concentration and vial size (semaglutide 1 mL at 2.5 mg/mL $80, falling to $65 at 200+ orders a month; tirzepatide from $100 per 1 mL vial), four monthly-volume bands (25-49, 50-99, 100-199, 200+) and an on-site price comparison calculator. List pricing is orderable with no call; volume pricing is quoted on a call.Re-read 2026-10-22 |
 AutoPilotRx | Model only, no rates | States pricing, state licensing and formularies are comparable in-portal and free for providers. No per-clinic negotiated pricing is stated. |
 Fizy Health | Model only, no rates | States pass-through pricing and zero platform fee. Pass-through is the pharmacy price rather than a per-clinic negotiated rate. |
 The Banyan Network | Model only, no rates | Publishes negotiated per-partner rates, net-30 terms, no membership or joining fees, and an all-inclusive definition covering medication, supplies, dispensing fees and shipping. States that rates depend on category, volume and partner, and are fixed in the agreement before a first order. No rate card or tiers are published.Re-read 2026-10-18 |
 CompoundingFinder | Model only, no rates | Compares pharmacies by price, turnaround, shipping and inactive ingredients, free and with no obligation. |
| Peptide Association Pharmacy Directory | Model only, no rates | States price ranges are tracked alongside accreditation and compounds. |
 Find My Chemist | Model only, no rates | Invites submitted prices and shows price information, but not provider-negotiated rates. |
 VitaRelay | Nothing published | No pricing is published; entry is book a call. |
 Ironsail Pharma / ImpetusOne | Nothing published | No pricing is published; the product sits behind a demo. |
| CLR RX | Nothing published | No pricing is published; entry is a private demo request. |
 Find My Compounder | Nothing published | No pricing is published. |
 APC / A4PC Pharmacy Locator | Nothing published | No pricing is published. |
Pricing shown is what each provider published at the time we recorded it and may change. Actual pricing varies by product, formulation, order volume, shipping, pharmacy, location and commercial terms. Confirm current pricing directly with the provider.